ClinicalTrials.gg
CompletedNCT01909466Updated Jul 1, 2015Results posted

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

A Phase 1 interventional study of Aripiprazole, OPC-14597 in Schizophrenia, Mental Disorder and Nervous System Diseases, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2015-07-01.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
60th of 125
141 · median 130
Started
2013
with 5 others
Phase 1
13 of 126
none open now
Registered
79th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 60th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2013, is one of 13 in phase 1, and was the 79th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia

Read the detailed description

This is a trial designed to assess the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia. The trial consists of a 113 day treatment period with a 28 day followup. The trial population will include male and female subjects between 18 and 64 years (inclusive), with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a prior history of tolerating aripiprazole per investigator's judgement.

03

Conditions studied

  • Schizophrenia
  • Mental Disorder
  • Nervous System Diseases

Keywords

  • OPC-14597
  • Aripiprazole
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female individuals between 18 and 64 years, inclusive, at the time of .
  • Prior history of tolerating aripiprazole per investigator's judgement.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have met DSMV-IV-TR criteria for substance dependence within the past 180 days.
  • Subjects who use more than one antipsychotic medication at screening.
  • Use of any CYP2D6 and inhibitors, or CYP3A4 inducers within 14 days prior to dosing and for the duration of the trial.
  • Subjects who participated in any clinical trial involving a psychotropic medication within 1 month prior to enrollment.
  • Subjects currently in an acute relapse of schizophrenia.
  • Subjects with a current DSMV-IV-TR diagnosis other than schizophrenia.
  • Subjects who are considered treatment-resistant to antipsychotic medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Other
    Gluteal Injection

    Drug: Aripiprazole, OPC-14597

  • Other
    Deltoid Injection

    Drug: Aripiprazole, OPC-14597

Interventions

  • 5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs).

    AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life threatening or required inpatient hospitalization or prolonged hospitalization. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

    Time frame: AEs were recorded from the time the informed consent was signed until follow-up for 28 days after last

  2. Mean Visual Analog Scale (VAS) Score for Rating of Pain at the Injection Site.

    Participants assessed the pain associated with injection of aripiprazole IM using the VAS instrument. This was done approximately 30 minutes pre-dose and 1 hour (±15 min) Post-dose on Days 1, 29, 57, 85 and 113. For the first injection, the pre-dose assessment was of the current injection site. For the injections 2 through 5, the pre-dose assessment was of the prior injection site. Investigator's Assessment of Most Recent Injection Site including pain, swelling, redness, and induration were reported in 4-point categorical scale (1 = absent, 2 = mild, 3 = moderate and 4 = severe) by first injection site at each injection.

    Time frame: Days 1 and 113

  3. Mean Change From Baseline in Suicidal Ideation Intensity Total Score Via Columbia-suicide Severity Rating Scale (C-SSRS).

    Suicidality was monitored throughout the trial using C-SSRS. The C-SSRS addresses the need for standardized classification of suicide reports to assess suicide risk. This scale consisted of Baseline evaluation that assessed the lifetime experience of the participant with suicidal events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit. The C-SSRS since last visit form were completed on Day 1 pre-dose and prior to dosing on Days 29, 57, 85, 113, 141/ Early Termination(ET) and prior to pharmacokinetics(PK) sampling on Days 8, 15, 22, 120, 127 and 134. The suicidal ideation intensity total score was the sum of suicidal ideation severity rating scores for frequency, duration, controllability, deterrents, and reasons for ideation. For each item, each participant got an intensity score from 0(none) to 5(worst). Therefore,the suicidal ideation intensity total score range from 0 to 25, with a score of 0 given for no suicidal ideation.

    Time frame: Baseline to Last Visit (Day 141)

  4. Mean Change From Baseline Measured by Extrapyramidal Symptoms (EPS) by Simpson-Angus Scale (SAS).

    The SAS consisted of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). The SAS Total Score was the sum of the scores for all 10 items. SAS total score can range from 10 to 50. Each item was rated on a 5-point scale, with a score of 1 =absence of symptoms and a score of 5 =severe condition.

    Time frame: Baseline to Week 20

  5. Mean Change From Baseline Measured by EPS by Abnormal Involuntary Movement Scale (AIMS).

    The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). These items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Overall AIMS scores range from 0 to 42.

    Time frame: Baseline to Week 20

  6. Mean Change From Baseline Measured by EPS by Barnes Akathisia Rating Scale (BARS).

    The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe).

    Time frame: Baseline to Week 20

Secondary outcomes

  1. Mean Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS).

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Week 20

  2. Mean Change From Baseline in PANSS Positive Sub-scale Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 20

  3. Mean Change From Baseline in PANSS Negative Sub-scale Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 20

  4. Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score.

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline to Week 20

  5. Clinical Global Impression-Improvement (CGI-I) Score.

    The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Baseline to Week 20

  6. Mean Change From Baseline in Total Score of Subject Well-being Under Neuroleptic Treatment-Short Form (SWN-S).

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. The total score from the scale ranges from 20 (bad subjective experience) to 120 (perfect subjective experience).

    Time frame: Baseline to Week 20+

  7. Mean Change From Baseline in Mental Functioning Score of SWN-S.

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

    Time frame: Baseline to Week 20

  8. Mean Change From Baseline in Self Control Score of SWN-S.

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

    Time frame: Baseline to Week 20

  9. Mean Change From Baseline in Physical Functioning Score of SWN-S.

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

    Time frame: Baseline to Week 20

  10. Mean Change From Baseline in Emotional Regulation Score of SWN-S.

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

    Time frame: Baseline to Week 20

  11. Mean Change From Baseline in Social Integration Score of SWN-S.

    The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

    Time frame: Baseline to Week 20

07

Results

Posted Jun 2, 2015

Participant flow

An open-label, multiple dose, multiple-site trial of adult participants with schizophrenia for the first application of aripiprazole intramuscular (IM) depot 400 mg in the gluteal or deltoid muscle (1:1 ratio) followed by 4 monthly administrations to the deltoid muscle site in all participants.

Participant flow — Overall Study
MilestoneGluteal/DeltoidDeltoid/Deltoid
Started6873
Completed4650
Not completed2223
Withdrew: Lost to follow-up57
Withdrew: Adverse event34
Withdrew: Met withdrawal criteria03
Withdrew: Physician decision20
Withdrew: Withdrawal by subject119
Withdrew: Lack of efficacy10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs).

AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life threatening or required inpatient hospitalization or prolonged hospitalization. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

Time frame:
AEs were recorded from the time the informed consent was signed until follow-up for 28 days after last
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs).
participantsAripiprazole IM Depot 400 mg - Total
Participants with TEAEs112
Participants with serious TEAEs4
Participants with non-serious TEAEs112
Participants with severe TEAEs2
PrimaryMean Visual Analog Scale (VAS) Score for Rating of Pain at the Injection Site.

Participants assessed the pain associated with injection of aripiprazole IM using the VAS instrument. This was done approximately 30 minutes pre-dose and 1 hour (±15 min) Post-dose on Days 1, 29, 57, 85 and 113. For the first injection, the pre-dose assessment was of the current injection site. For the injections 2 through 5, the pre-dose assessment was of the prior injection site. Investigator's Assessment of Most Recent Injection Site including pain, swelling, redness, and induration were reported in 4-point categorical scale (1 = absent, 2 = mild, 3 = moderate and 4 = severe) by first injection site at each injection.

Time frame:
Days 1 and 113
Reported as:
Mean · Units on a scale
Mean Visual Analog Scale (VAS) Score for Rating of Pain at the Injection Site.
Units on a scaleAripiprazole IM Depot 400 mg - Total
First injection (Day 1)2.0 ± 4.4
Last injection (Day 113)1.2 ± 3.4
PrimaryMean Change From Baseline in Suicidal Ideation Intensity Total Score Via Columbia-suicide Severity Rating Scale (C-SSRS).

Suicidality was monitored throughout the trial using C-SSRS. The C-SSRS addresses the need for standardized classification of suicide reports to assess suicide risk. This scale consisted of Baseline evaluation that assessed the lifetime experience of the participant with suicidal events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit. The C-SSRS since last visit form were completed on Day 1 pre-dose and prior to dosing on Days 29, 57, 85, 113, 141/ Early Termination(ET) and prior to pharmacokinetics(PK) sampling on Days 8, 15, 22, 120, 127 and 134. The suicidal ideation intensity total score was the sum of suicidal ideation severity rating scores for frequency, duration, controllability, deterrents, and reasons for ideation. For each item, each participant got an intensity score from 0(none) to 5(worst). Therefore,the suicidal ideation intensity total score range from 0 to 25, with a score of 0 given for no suicidal ideation.

Time frame:
Baseline to Last Visit (Day 141)
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Suicidal Ideation Intensity Total Score Via Columbia-suicide Severity Rating Scale (C-SSRS).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 1 (N= 135)0.0 ± 0.0
Week 2 (N= 132)0.0 ± 0.0
Week 3 (N= 131)0.0 ± 0.0
Week 4 (N= 129)0.2 ± 1.3
Week 8 (N= 112)0.1 ± 1.0
Week 12 (N= 109)0.1 ± 1.1
Week 16 (N= 99)0.0 ± 0.0
Week 17 (N=100)0.0 ± 0.0
Week 18 (N= 98)0.0 ± 0.0
Week 19 (N= 99)0.0 ± 0.0
Week 20 (N= 97)0.0 ± 0.0
Last Visit (N= 136)0.1 ± 0.6
PrimaryMean Change From Baseline Measured by Extrapyramidal Symptoms (EPS) by Simpson-Angus Scale (SAS).

The SAS consisted of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). The SAS Total Score was the sum of the scores for all 10 items. SAS total score can range from 10 to 50. Each item was rated on a 5-point scale, with a score of 1 =absence of symptoms and a score of 5 =severe condition.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline Measured by Extrapyramidal Symptoms (EPS) by Simpson-Angus Scale (SAS).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 1(N= 135)0.01 ± 0.89
Week 2 (N= 136)0.04 ± 0.83
Week 3 (N= 136)-0.02 ± 1.08
Week 4 (N= 136)0.01 ± 0.98
Week 8 (N= 136)0.02 ± 1.11
Week 12 (N= 136)0.04 ± 1.17
Week 16 (N= 136)0.07 ± 1.04
Week 20 (N= 136)0.07 ± 1.20
PrimaryMean Change From Baseline Measured by EPS by Abnormal Involuntary Movement Scale (AIMS).

The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). These items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Overall AIMS scores range from 0 to 42.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline Measured by EPS by Abnormal Involuntary Movement Scale (AIMS).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 1(N= 135)-0.03 ± 0.42
Week 2 (N= 136)-0.05 ± 0.37
Week 3 (N= 136)-0.01 ± 0.52
Week 4 (N= 136)-0.03 ± 0.50
Week 8 (N= 136)-0.05 ± 0.53
Week 12 (N= 136)0.00 ± 0.40
Week 16 (N= 136)-0.03 ± 0.52
Week 20 (N= 136)0.03 ± 0.64
PrimaryMean Change From Baseline Measured by EPS by Barnes Akathisia Rating Scale (BARS).

The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe).

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline Measured by EPS by Barnes Akathisia Rating Scale (BARS).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 1(N=135)0.03 ± 0.47
Week 2 (N=136)0.08 ± 0.50
Week 3 (N=136)0.08 ± 0.57
Week 4 (N=136)0.06 ± 0.47
Week 8 (N=136)0.11 ± 0.59
Week 12 (N=136)0.06 ± 0.51
Week 16 (N=136)0.06 ± 0.51
Week 20 (N=136)0.04 ± 0.47
SecondaryMean Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS).

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.94 ± 9.42
Week 20 (N= 128)-2.23 ± 10.95
SecondaryMean Change From Baseline in PANSS Positive Sub-scale Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Positive Sub-scale Score.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.14 ± 3.18
Week 20 (N= 128)-0.52 ± 3.84
SecondaryMean Change From Baseline in PANSS Negative Sub-scale Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Negative Sub-scale Score.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.30 ± 3.56
Week 20 (N= 128)-0.33 ± 3.79
SecondaryMean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score.

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.02 ± 0.57
Week 20 (N= 128)-0.09 ± 0.61
SecondaryClinical Global Impression-Improvement (CGI-I) Score.

The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Clinical Global Impression-Improvement (CGI-I) Score.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)3.86 ± 0.78
Week 20 (N= 128)3.70 ± 0.98
SecondaryMean Change From Baseline in Total Score of Subject Well-being Under Neuroleptic Treatment-Short Form (SWN-S).

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. The total score from the scale ranges from 20 (bad subjective experience) to 120 (perfect subjective experience).

Time frame:
Baseline to Week 20+
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Total Score of Subject Well-being Under Neuroleptic Treatment-Short Form (SWN-S).
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-1.17 ± 15.95
Week 20 (N= 128)-0.81 ± 17.09
SecondaryMean Change From Baseline in Mental Functioning Score of SWN-S.

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Mental Functioning Score of SWN-S.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.18 ± 4.85
Week 20 (N= 128)0.01 ± 4.83
SecondaryMean Change From Baseline in Self Control Score of SWN-S.

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Self Control Score of SWN-S.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.47 ± 3.90
Week 20 (N= 128)-0.64 ± 4.14
SecondaryMean Change From Baseline in Physical Functioning Score of SWN-S.

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Physical Functioning Score of SWN-S.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.39 ± 4.44
Week 20 (N= 128)-0.37 ± 4.34
SecondaryMean Change From Baseline in Emotional Regulation Score of SWN-S.

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Emotional Regulation Score of SWN-S.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)0.30 ± 3.36
Week 20 (N= 128)0.46 ± 4.05
SecondaryMean Change From Baseline in Social Integration Score of SWN-S.

The participant's feeling of their own well-being was assessed using the 20 question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of 1 being while receiving antipsychotic medication. The questionnaire consisted of 20 items and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', response choices and scoring were as follows: not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, very much = 6. For items marked with a '-', the scoring was reversed; response choices and scoring were as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 0 (none) to 6 (severe), with higher scores indicating stronger subjective feelings of deficit.

Time frame:
Baseline to Week 20
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Social Integration Score of SWN-S.
Units on a scaleAripiprazole IM Depot 400 mg - Total
Week 8 (N= 128)-0.47 ± 4.28
Week 20 (N= 128)-0.32 ± 4.43

Adverse events

Collected over Adverse events were reported from the signing of the ICF until follow-up for up to 28 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot 400 mg - Total—4/138 (2.9%)112/138 (81.2%)
Most frequent serious events
Most frequent serious events
EventAripiprazole IM Depot 400 mg - Total
SchizophreniaPsychiatric disorders2/138
Atrial fibrillationCardiac disorders1/138
Psychotic disorderPsychiatric disorders1/138
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAripiprazole IM Depot 400 mg - Total
Injection site painGeneral disorders38/138
Weight increasedInvestigations17/138
HeadacheNervous system disorders16/138
ToothacheGastrointestinal disorders11/138
Upper respiratory tract infectionInfections and infestations11/138
AkathisiaNervous system disorders11/138
DyspepsiaGastrointestinal disorders9/138
NauseaGastrointestinal disorders9/138
RestlessnessPsychiatric disorders8/138
DiarrhoeaGastrointestinal disorders7/138

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot 400 mg - Total
Mean43.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot 400 mg - Total
Female32
Male109
08

Study locations

11 sites
  • Comprehensive Clinical Development
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • CNRI-San Diego
    San Diego, California 92101, United States
  • Comprehensive Clinical Development
    Washington, District of Columbia 20016, United States
  • Scientific Clinical Research, Inc.
    Ft. Lauderdale, Florida 33308, United States
  • Compass Research North, LLC
    Leesburg, Florida 34748, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri 63118, United States
  • CRI Lifetree
    Marlton, New Jersey 08053, United States
  • CRI Lifetree
    Philadelphia, Pennsylvania 19139, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
09

References and documents

Publications

  • Raoufinia A, Peters-Strickland T, Nylander AG, Baker RA, Eramo A, Jin N, Bricmont P, Repella J, McQuade RD, Hertel P, Larsen F. Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. Int J Neuropsychopharmacol. 2017 Apr 1;20(4):295-304. doi: 10.1093/ijnp/pyw116. PubMed 28204607 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Mar 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2013
First posted
Jul 26, 2013
Start
Jul 2013
Primary completionActual
Mar 2014
CompletionActual
Apr 2014
Results first posted
Jun 2, 2015
Last update
Jul 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01909466
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 26, 2013
Start date
Jul 2013
Primary completion
Mar 2014
Completion
Apr 2014
Results posted
Jun 2, 2015
Last update
Jul 1, 2015

Study contacts

Kimberly Largay, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion